NetworkNewsBreaks – NanoViricides (NYSE American: NNVC) Releases Q2 Financial Report
NanoViricides (NYSE American: NNVC), a global leader in broad-spectrum antiviral nanomedicines, has filed on its second-quarter 2024 financial results for the period ending March 31, 2024; the company filed the report with the U.S. Securities and Exchange Commission on May 14, 2024. Notable numbers from the report include cash and cash equivalent totaling $3.51 million, with additional agreements adding approximately $2.5 million more in available cash with property, equipment and intangible assets reported at approximately $7.92 million. The report also noted that the company has a clinical asset in NV-387 that is available for partnering, which could result in a…







